CClinicalTrials.gg
CompletedNCT05777720Updated Feb 19, 2026

Cluster-Randomized Trial of Air Filtration and Ventilation to Reduce Covid19 Spread in Homes

An interventional study of Filtration Fan and Safe-home pamphlet in Covid19, sponsored by Stanford University. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Stanford University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
214
Allocation
Randomized
Sex
All
01

Study summary

Investigators are evaluating whether an intervention consisting of box-fans with MERV 16 filters ("filtration fans") and recommendations for improving ventilation in the home can reduce secondary spread of Covid19 from an index case to susceptible contacts within the home.

02

Conditions studied

  • Covid19

Keywords

  • ventilation
  • air filtration
  • Covid19
  • SARS CoV 2
  • household transmission
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 214 is above the median of 100 across 4,099 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Household members live in a shared space (apartment, home) with others (as opposed to renting single rooms in a shared space, for example)
  • At least 3 other people live in the household aside from index case

Exclusion criteria

Exclusion Criteria:

  • If index case test positive day was over 2 days prior
  • If half or more household members are thought to be infected already
  • If household has fewer than 3 contacts interested in participating in the study
  • If fewer than 3 contacts are expected to be present in the house for a majority of the following 7 days
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
214 participants (actual)

Study arms

  • No intervention
    Control

    No intervention will be administered in this arm. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will provide a link to the basic CDC isolation guidelines which would be part of standard of care. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.

  • Experimental
    Intervention

    Families are provided with one filtration fan unit per room in their home (and one for the index case; if the family lives in a studio, they would receive 2 units). Investigators will advise families on ventilation improvements in their home. Investigators will provide an instructional pamphlet that describes how the fans work and the importance of ventilation. Investigators will follow-up on day 3-4 to check in and run through a checklist to ensure the fans are working and ventilation improvements are being attempted. Investigators will give families a CO2 monitor to measure average CO2 levels in the home. Investigators will test family members at day 0-1 for baseline testing; and again on day 7 for assessing secondary transmission among susceptible contacts.

    Device: Filtration Fan · Behavioral: Safe-home pamphlet · Behavioral: Mid-week phone call

Interventions

  • DeviceFiltration Fan

    Investigators are using box fans with attached MERV16 filters, a design that has been tested and published in the scientific literature.

  • BehavioralSafe-home pamphlet

    The pamphlet has information on how the filtration fans work through visual images; and images of ventilation improvements in the home through opening windows.

  • BehavioralMid-week phone call

    On day 3-4 of the study, the study coordinator assigned to the house will call and check in regarding the filtration fan usage and remind families about the importance of filtration and ventilation.

06

What researchers measure

Primary outcomes

  1. Incidence of Covid19

    Investigators will measure the incidence of Covid19 in susceptible contacts on day 7.

    Time frame: 7th day since enrollment in the trial

Secondary outcomes

  1. Incidence of new upper respiratory symptoms

    Investigators will measure reported new upper respiratory symptoms in susceptible contacts.

    Time frame: 7th day since enrollment in the trial

  2. Average CO2 levels

    Investigators will measure 7 day average CO2 levels in the home (measured in parts per million)

    Time frame: 7 days

07

Study locations

2 sites
  • San Mateo Medical Center
    San Mateo, California 94403, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05777720
Lead sponsor
Stanford University
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Abraar Karan (Post-Doctoral Fellow, Stanford University) — Principal investigator
First posted
Mar 21, 2023
Start date
Jan 30, 2023
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Feb 19, 2026

Study contacts

Yvonne Maldonado, MD
study director · Stanford University
Abraar Karan, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion